BioPlus Acquisition Corp. Balance Sheet

Ask AI

Financial Statements

In millions of USD, except per-share amounts

	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021
ASSETS
Current assets
Cash
Prepaid expenses
Total Current Assets
Prepaid expenses
Cash and investments held in Trust Account
TOTAL ASSETS
LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS' DEFICIT
Current liabilities
Accrued expenses
Accrued offering costs
Advance from related parties
Working capital loan
Total Current Liabilities
Sponsor Loan
Deferred underwriting fee payable
TOTAL LIABILITIES
Class A ordinary shares subject to possible redemption; $0.0001 par value, 13,057,477 and 23,000,000 shares issued and outstanding at approximately $10.60 and $10.34 per share, redemption value as of June 30, 2023 and December 31, 2022, respectively
Class A Ordinary Shares
Total class A ordinary shares subject to possible redemption; $0.0001 par value, 13,057,477 and 23,000,000 shares issued and outstanding at approximately $10.60 and $10.34 per share, redemption value as of June 30, 2023 and December 31, 2022, respectively
SHAREHOLDERS' DEFICIT
Common stock value
Class A Ordinary Shares
Common Class B
Accumulated deficit
TOTAL SHAREHOLDERS' DEFICIT
TOTAL LIABILITIES, CLASS A ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS' DEFICIT

Comments